AbbVie ABBV announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular ...

We recently published a list of 12 Most Profitable Growth Stocks To Invest In. In this article, we are going to take a look ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at ...

Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with ...